Related Experiment Videos
Electron microscopic DOPA reaction test for oculocutaneous albinism
Y Takizawa1, S Kato, J Matsunaga
1Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. takizawa@med.keio.ac.jp
Archives of Dermatological Research
|August 10, 2000
Summary
Oculocutaneous albinism (OCA) subtypes were identified using tyrosinase gene analysis and EM-DOPA testing. This approach accurately assesses tyrosinase activity, crucial for diagnosing OCA1A and OCA1B, aiding patient prognosis.
Area of Science:
- Genetics and Molecular Biology
- Dermatology and Pigmentary Disorders
Background:
- Oculocutaneous albinism (OCA) is a group of autosomal recessive disorders affecting melanin production.
- Tyrosinase-related OCA (OCA1) results from mutations in the tyrosinase gene, leading to reduced or absent melanin.
- OCA1A (severe) shows no tyrosinase activity, while OCA1B (mild) has varying pigment levels.
Purpose of the Study:
- To determine tyrosinase activity in melanocytes using the EM-DOPA reaction test.
- To analyze tyrosinase gene mutations in Japanese patients with OCA.
- To correlate genetic findings and tyrosinase activity with clinical phenotypes for improved diagnosis and prognosis.
Main Methods:
- Skin samples from nine Japanese OCA patients were used.
- Electron microscopic dihydroxyphenylalanine (EM-DOPA) reaction test was performed to assess melanocyte tyrosinase activity.
- Tyrosinase gene sequencing was conducted to identify mutations.
Main Results:
- OCA1A-associated mutations (P310insC, R77Q, R278X) were identified in 11 out of 18 alleles.
- Patients with homozygous OCA1A mutations showed no tyrosinase activity and severe albinism.
- One patient with a heterozygous R77Q mutation exhibited reduced tyrosinase activity (OCA1B) and a milder phenotype.
Conclusions:
- The EM-DOPA reaction test is a reliable method for assessing tyrosinase activity in OCA.
- Combining genetic analysis with functional assays aids in precise OCA subtype identification.
- Accurate subtyping of OCA is essential for predicting disease progression and patient outcomes.